Pneumococcal Vaccination Recommendation and Completion Rates Among Patients With Inflammatory Bowel Disease and Barriers to Vaccination.
Sonya S Dasharathy, Folasade P May, Anthony Myint, Liu Yang, Harman K Rahal, Vivy Cusumano, Philip A Kozan, Sarina C Lowe, Peter Y Beah, Berkeley N Limketkai, Jenny S Sauk
Author Information
Sonya S Dasharathy: Vatche and Tamar Manoukian Division of Digestive Diseases. ORCID
Folasade P May: Vatche and Tamar Manoukian Division of Digestive Diseases.
Anthony Myint: Vatche and Tamar Manoukian Division of Digestive Diseases.
Liu Yang: Vatche and Tamar Manoukian Division of Digestive Diseases.
Harman K Rahal: Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA.
Vivy Cusumano: Vatche and Tamar Manoukian Division of Digestive Diseases.
Philip A Kozan: Department of Medicine, David Geffen School of Medicine, UCLA.
Sarina C Lowe: Vatche and Tamar Manoukian Division of Digestive Diseases.
Peter Y Beah: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Berkeley N Limketkai: Vatche and Tamar Manoukian Division of Digestive Diseases.
Jenny S Sauk: Vatche and Tamar Manoukian Division of Digestive Diseases.
BACKGROUND: Guidelines for inflammatory bowel disease (IBD) patients receiving immunosuppression encouraged both the pneumococcal polysaccharide vaccine (PPSV23) and the pneumococcal conjugate vaccine (PCV13). We aimed to evaluate which pneumococcal vaccines are recommended and administered, and to understand provider and IBD patient knowledge regarding pneumococcal vaccinations. METHODS: We performed a retrospective, cross-sectional analysis of 357 adult IBD patients on immunosuppression in our health care system. Patient demographics and clinical characteristics were collected. The primary outcome was rate of documented vaccinations recommended by providers; the secondary outcome was rate of receipt of the vaccines. We identified factors associated with receipt of any pneumococcal vaccine through multivariable logistic regression. We also performed provider and IBD patient surveys to understand provider and patient knowledge regarding pneumococcal vaccines. We used �� 2 and Fisher exact tests to assess survey responses. RESULTS: Fifty seven percent of IBD patients had any pneumococcal vaccination recommended and 35% had recommendations for both PPSV23 and PCV13. Forty percent received any pneumococcal vaccine and 18% received both vaccines. In multivariable analyses, increasing age (adjusted odds ratio: 1.03, 95% CI: 1.01-1.05) was associated with receipt of any pneumococcal vaccine, after adjusting for gender, race, insurance, disease activity, and time seen in our gastroenterology clinics. In the survey study, on average, 59% of providers correctly answered questions regarding pneumococcal vaccination indications. CONCLUSION: In our health care system, while recommendation for any pneumococcal vaccination was >50%, receipt of both PPSV23 and PCV13 was low. Simplified vaccine regimens (ie, PCV20) will likely improve vaccination rates.
References
Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240���248.
Kants�� B, Simonsen J, Hoffmann S, et al. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: A Nationwide Danish Cohort Study 1977���2013. Am J Gastroenterol. 2015;110:1582���1587.
Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohn���s Colitis. 2013;7:107���112.
Love BL, Finney CJ, Gaidos JKJ. Effectiveness of conjugate and polysaccharide pneumococcal vaccines for prevention of severe pneumococcal disease among inflammatory bowel disease patients. J Crohn���s Colitis. 2021;15:1279���1283.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014;58:e44���e100.
Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112:241���258.
Brill JV, Higgins PD, Inadomi J, et al. American Gastroenterological Association Crohn���s and Colitis Foundation of America American Gastroenterological Association Staff Physician Consortium for Performance Improvement (PCPI) Staff Physician Consortium for Performance Improvement (PCPI) Internal Medicine Healthcare Payor Community Consumer Representative Co-Chairs Work Group Members. 2010.
ACIP Vaccine Recommendations and Schedules | CDC. 2022. Available at: https://www.cdc.gov/vaccines/acip/recommendations.html . Accessed January 3, 2022.
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among US Adults: Updated Recommendations of the Advisory Committee on Immunization Practices���United States, 2022. MMWR Recomm Rep. 2022;71:109���117.
Loubet P, Verger P, Abitbol V, et al. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50:563���567.
Case DJ, Copeland LA, Stock EM, et al. Pneumococcal vaccination rates in VHA patients with inflammatory bowel disease. Medicine (Baltimore). 2015;94:e417.
Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11:396���401.
Coenen S, Weyts E, Jorissen C, et al. Effects of education and information on vaccination behavior in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:318���324.
Parker S, Chambers White L, Spangler C, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19:1809���1814.
Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834���1840.
Sitte J, Frentiu E, Baumann C, et al. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: a prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019;49:84���90.
Pham H-V, Hasan I, Udaltsova N, et al. Rates and predictors of vaccinations among inflammatory bowel disease patients receiving anti-tumor necrosis factor agents. Dig Dis Sci. 2018;63:209���217.
Chan W, Salazar E, Lim TG, et al. Vaccinations and inflammatory bowel disease���a systematic review. Dig Liver Dis. 2021;53:1079���1088.
Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148���154.
Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042���1047.
Wasan SK, Calderwood AH, Long MD, et al. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. 2013.
Bhat S, Caldera F, Farraye FA. Barriers to administering vaccines in Inflammatory Bowel Disease Centers. Inflamm Bowel Dis. 2014;20:246���250.
